Fundraising FoxMingSight Pharmaceuticals
San Diego, US · Delaware corporation
Find your way into MingSight Pharmaceuticals
Sign up to see every warm intro you have to MingSight Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the MingSight Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
MingSight Pharmaceuticals is a clinical-stage biopharmaceutical company developing MS-553, an orally administered selective protein kinase C (PKC) inhibitor. Its lead candidate targets diabetic macular edema and diabetic retinopathy in ophthalmology, as well as chronic lymphocytic leukemia and small lymphocytic lymphoma in oncology.
Founders & leadership
MN
Michael NiesmanCo-founder
KZ
Kai ZhangChief Executive Officer
DZ
Dr. ZhangCo-founder & CEO
DN
Dr. NiesmanCo-founder
XX
Xintao XiaNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$10M disclosed across 1 round · 2021
▶$10MraisedNov 2021 · 2 investors · PharmaceuticalsRule 506(b)
▶$10MraisedNov 2021 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Michael NiesmanExecutive Officer, Director
- Xintao XiaDirector
- Kai ZhangExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does MingSight Pharmaceuticals do?
- MingSight Pharmaceuticals is a clinical-stage biopharmaceutical company developing MS-553, an orally administered selective protein kinase C (PKC) inhibitor. Its lead candidate targets diabetic macular edema and diabetic retinopathy in ophthalmology, as well as chronic lymphocytic leukemia and small lymphocytic lymphoma in oncology.
- Who founded MingSight Pharmaceuticals?
- MingSight Pharmaceuticals was founded by Michael Niesman, Kai Zhang, Dr. Zhang, Dr. Niesman.
- How much funding has MingSight Pharmaceuticals raised?
- MingSight Pharmaceuticals has disclosed $10M raised across 1 round.
- Where is MingSight Pharmaceuticals headquartered?
- MingSight Pharmaceuticals is headquartered in San Diego, US.